Lim SM - Search Results

1

BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancer.

Lim SM, Schalm SS, Lee EJ, Park S, Conti C, Millet YA, Woessner R, Zhang Z, Tavera-Mendoza LE, Stevison F, Albayya F, Dineen TA, Hsieh J, Oh SY, Zalutskaya A, Rotow J, Goto K, Lee DH, Yun MR, Cho BC. Lim SM, et al. Ther Adv Med Oncol. 2024 Oct 21;16:17588359241280689. doi: 10.1177/17588359241280689. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39444426 Free PMC article.

2

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.

Lim SM, Park HS, Kim S, Kim S, Ali SM, Greenbowe JR, Yang IS, Kwon NJ, Lee JL, Ryu MH, Ahn JH, Lee J, Lee MG, Kim HS, Kim H, Kim HR, Moon YW, Chung HC, Kim JH, Kang YK, Cho BC. Lim SM, et al. Oncotarget. 2016 Mar 1;7(9):10547-56. doi: 10.18632/oncotarget.7234. Oncotarget. 2016. PMID: 26859683 Free PMC article.

3

A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).

Lim SM, Cho BC, Kim SW, Kang SY, Heo DS, Kim HT, Lee DH, Kim DW, Jung M, Choi JH, Shim HS, Choi JR, Kim JH. Lim SM, et al. Lung Cancer. 2016 Mar;93:1-8. doi: 10.1016/j.lungcan.2015.12.005. Epub 2015 Dec 29. Lung Cancer. 2016. PMID: 26898607 Clinical Trial.

4

Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.

Lim SM, Kim EY, Kim HR, Ali SM, Greenbowe JR, Shim HS, Chang H, Lim S, Paik S, Cho BC. Lim SM, et al. Among authors: lim s. Oncotarget. 2016 Apr 26;7(17):24172-8. doi: 10.18632/oncotarget.8138. Oncotarget. 2016. PMID: 26992220 Free PMC article.

5

ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.

Kang HN, Kim SH, Yun MR, Kim HR, Lim SM, Kim MS, Hong KW, Kim SM, Kim H, Pyo KH, Park HJ, Han JY, Youn HA, Chang KH, Cho BC. Kang HN, et al. Among authors: lim sm. Lung Cancer. 2016 May;95:57-64. doi: 10.1016/j.lungcan.2016.02.013. Epub 2016 Feb 27. Lung Cancer. 2016. PMID: 27040853

6

Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).

Lim SM, Kim HR, Cho EK, Min YJ, Ahn JS, Ahn MJ, Park K, Cho BC, Lee JH, Jeong HC, Kim EK, Kim JH. Lim SM, et al. Oncotarget. 2016 Jun 14;7(24):36311-36320. doi: 10.18632/oncotarget.8904. Oncotarget. 2016. PMID: 27121209 Free PMC article.

7

Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma.

Lim SM, Yoo JE, Lim KH, Meng Tai DW, Cho BC, Park YN. Lim SM, et al. Among authors: lim kh. Cancer Res Treat. 2017 Jan;49(1):185-192. doi: 10.4143/crt.2015.497. Epub 2016 Apr 27. Cancer Res Treat. 2017. PMID: 27121721 Free PMC article.

8

EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines.

Kim SM, Kim H, Jang KW, Kim MH, Sohn J, Yun MR, Kang HN, Kang CW, Kim HR, Lim SM, Moon YW, Kim JH, Paik S, Cho BC. Kim SM, et al. Among authors: lim sm. Mol Cancer Ther. 2016 Jul;15(7):1627-36. doi: 10.1158/1535-7163.MCT-15-0375. Epub 2016 May 11. Mol Cancer Ther. 2016. Retraction in: Mol Cancer Ther. 2017 Oct;16(10):2326. doi: 10.1158/1535-7163.MCT-17-0547 PMID: 27196768 Retracted.

9

Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.

Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim SM, Kim H, Kang HN, Lee JM, Kim SG, Park CW, Chang H, Shim HS, Lee HW, Cho BC. Pyo KH, et al. Among authors: lim sm. J Thorac Oncol. 2017 Mar;12(3):491-500. doi: 10.1016/j.jtho.2016.10.022. Epub 2016 Nov 9. J Thorac Oncol. 2017. PMID: 27836576 Free article.

10

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.

Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, Cho EK, Lee SS, Kim BS, Choi MY, Shim HS, Chung JH, La Choi Y, Lee MJ, Kim M, Kim JH, Ali SM, Ahn MJ, Cho BC. Lim SM, et al. J Clin Oncol. 2017 Aug 10;35(23):2613-2618. doi: 10.1200/JCO.2016.71.3701. Epub 2017 May 18. J Clin Oncol. 2017. PMID: 28520527 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

952 results

Search Page

Filters